Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Charles University, Czech Republic AstraZeneca |
---|---|
Information provided by: | Charles University, Czech Republic |
ClinicalTrials.gov Identifier: | NCT00430833 |
The primary hypothesis of the study is that treatment with AT1-R antagonist in patients with nonobstructive form of HCM will be first save, second will cause regression of myocardial hypertrophy.
Condition | Intervention | Phase |
---|---|---|
Hypertrophic Cardiomyopathy |
Drug: candesartan |
Phase II |
Study Type: | Interventional |
Study Design: | Randomized, Double-Blind, Placebo Control, Parallel Assignment |
Official Title: | Candesartan Use in Hypertrophic and Non-Obstructive Cardiomyopathy Estate (The CHANCE): a Double-Blind, Placebo-Controlled, Randomized, Multicenter Study |
Patients will be randomly assigned in 1:1 ratio either to candesartan (target dose 32 mg once daily) or matching placebo. The initial dose of the study drug will be 8 mg once daily. Study drug dose will be then doubled as tolerated every 2 weeks while aiming for a target dose of 32 mg once daily.
Monitoring of blood pressure, serum creatinine, serum potassium and pressure gradient in LV outflow tract will be performed during dose increase.
Patients will be observed clinically at 3, 6, and 12 months after the maintenance dose was reached. Exercise tolerance will be assessed by bicycle ergometry, presence of malignant arrhythmias by Holter monitoring, extent of LV hypertrophy by 2-dimensional echocardiography, and LV outflow tract pressure gradient by Doppler echocardiography at baseline and 12-month follow-up.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Czech Republic | |
Cardiocenter, Third Faculty of Medicine, Charles University | |
Prague, Czech Republic, 10034 |
Principal Investigator: | Martin Penicka, PhD | Charles University, Prague, Czech Republic |
Study ID Numbers: | 9164 |
Study First Received: | January 31, 2007 |
Last Updated: | January 31, 2007 |
ClinicalTrials.gov Identifier: | NCT00430833 History of Changes |
Health Authority: | Czech Republic: State Institute for Drug Control |
Pathological Conditions, Anatomical Heart Diseases Constriction, Pathologic Cardiovascular Agents Angiotensin II Antihypertensive Agents Cardiomyopathies |
Heart Valve Diseases Candesartan cilexetil Angiotensin II Type 1 Receptor Blockers Hypertrophy Cardiomyopathy, Hypertrophic Candesartan Aortic Valve Stenosis |
Pathological Conditions, Anatomical Heart Diseases Molecular Mechanisms of Pharmacological Action Cardiovascular Agents Antihypertensive Agents Cardiomyopathies Pharmacologic Actions Heart Valve Diseases Angiotensin II Type 1 Receptor Blockers |
Candesartan cilexetil Hypertrophy Aortic Stenosis, Subvalvular Therapeutic Uses Cardiomyopathy, Hypertrophic Candesartan Cardiovascular Diseases Aortic Valve Stenosis |